Winterlight Labs Inc., a Toronto-based developer of AI vocal technology to detect central nervous system disorders and track efficacy of treatments, raised CAD 5.6m in funding.
The round was led by Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), via its venture capital arm, Hikma Ventures, with participation from First Star Ventures, Pacific Health Ventures, existing investor Grey Sky Venture Partners and other investors.
The company intends to use the funds to extend its technology to additional indications, such as schizophrenia and multiple sclerosis, as well as additional languages.
Led by Liam Kaufman, Co-founder and CEO, Winterlight Labs is developing proprietary Artificial Intelligence (AI) technology that melds computational linguistics, cognitive neuroscience, and machine learning to help healthcare professionals assess and analyse patients’ cognitive health – including memory, thinking and reasoning – from vocal markers captured in short snippets of speech on a tablet computer. Using a one-minute sample of a patient’s natural speech, Winterlight’s approach can detect various cognitive and mental disorders, such as dementia and aphasia amongst others, and then monitor the efficacy of treatments.